問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kuang Tien General Hospital (在職)

Division of Nephrology

Division of Endocrinology

Division of Cardiovascular Diseases

更新時間：2023-09-19

黃世忠
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃世忠

List

13Cases

2025-07-01 - 2030-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2024-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting9Sites

2024-12-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2025-12-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2023-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting5Sites

2025-06-01 - 2027-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2010-11-01 - 2012-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-05-01 - 2021-05-01

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-01-10 - 2015-12-31

Phase III

A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C

  • Condition/Disease

    Hyperlipidemia

  • Test Drug

    MK859/Placebo

Participate Sites
9Sites

Terminated9Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB